Hinge Health initiated with a Buy at Truist

Truist initiated coverage of Hinge Health (HNGE) with a Buy rating and $48 price target Hinge is a market leader in digital musculoskeletal care with “enduring structural advantages,” the analyst tells investors in a research note. The firm says the company’s “robust” outcomes data, extensive partner network, AI-enabled platform, and “compelling economics create a flywheel of adoption, retention, and expansion.” Truist sees long-term value creation potential.